BR112014001516A2 - peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico - Google Patents

peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico

Info

Publication number
BR112014001516A2
BR112014001516A2 BR112014001516A BR112014001516A BR112014001516A2 BR 112014001516 A2 BR112014001516 A2 BR 112014001516A2 BR 112014001516 A BR112014001516 A BR 112014001516A BR 112014001516 A BR112014001516 A BR 112014001516A BR 112014001516 A2 BR112014001516 A2 BR 112014001516A2
Authority
BR
Brazil
Prior art keywords
vaccination
pml
proteins
diagnostic applications
polyoma
Prior art date
Application number
BR112014001516A
Other languages
English (en)
Inventor
Jelcic Ilijas
Sospedra Mireia
Martin Roland
Yousef Sara
Schippling Sven
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of BR112014001516A2 publication Critical patent/BR112014001516A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico". a presente invenção refere-se ao campo de vacinação ou imunização, em particular, vacinação terapêutica e diagnóstico. são descritas composições farmacêuticas e kits capazes de ativar uma resposta imunológica protetora contra o vírus polioma jc (jcv), que podem ser utilizados, por exemplo, para a terapia ou para a prevenção de leucoencefalopatia multifocal progressiva (pml) e/ou síndrome inflamatória de reconstituição imunológica da leucoencefalopatia multifocal progressiva (pml-iris). os indivíduos em perigo de tal pml ou pml-iris podem, por exemplo, ser pacientes imunocomprometidos ou imunossuprimidos ou pacientes que possuem uma doença autoimune qualificados para o tratamento imunossupressor. a invenção refere-se ainda às composições que compreendem pelo menos um epitopo de cd4+ de uma proteína de jcv e aos usos terapêuticos, profiláticos e de diagnóstico das mesmas.
BR112014001516A 2011-07-22 2012-07-23 peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico BR112014001516A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11006031A EP2548567A1 (en) 2011-07-22 2011-07-22 Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
PCT/EP2012/064445 WO2013014134A2 (en) 2011-07-22 2012-07-23 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications

Publications (1)

Publication Number Publication Date
BR112014001516A2 true BR112014001516A2 (pt) 2017-02-14

Family

ID=46548481

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001516A BR112014001516A2 (pt) 2011-07-22 2012-07-23 peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico

Country Status (12)

Country Link
US (1) US9738690B2 (pt)
EP (2) EP2548567A1 (pt)
JP (1) JP2014520877A (pt)
KR (1) KR20140062702A (pt)
CN (1) CN103826653A (pt)
AU (1) AU2012288955B2 (pt)
BR (1) BR112014001516A2 (pt)
CA (1) CA2842543A1 (pt)
EA (1) EA201490322A1 (pt)
HK (1) HK1198517A1 (pt)
MX (1) MX2014000776A (pt)
WO (1) WO2013014134A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065367A1 (en) * 2011-12-12 2015-03-05 Janssen Diagnostics Bvba Polyomavirus peptide sequences
WO2014201034A2 (en) * 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
EP2926831A1 (en) * 2014-03-31 2015-10-07 Ruprecht-Karls-Universität Heidelberg CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
WO2016104046A1 (ja) * 2014-12-22 2016-06-30 日東電工株式会社 透明導電性フィルム
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
CN113278634B (zh) * 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DE10131145B4 (de) 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
JP4840792B2 (ja) * 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
US7612039B2 (en) * 2002-06-12 2009-11-03 Temple University - Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
JP2005341864A (ja) * 2004-06-02 2005-12-15 Japan Science & Technology Agency Ｊｃウイルスの粒子形成阻害剤
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
US20080057079A1 (en) 2006-08-31 2008-03-06 Baylor Research Institute JC Virus Vaccine
CN100595765C (zh) * 2008-06-30 2010-03-24 腾讯科技（深圳）有限公司 基于媒体播放器的关键词内容发布方法及系统
CN102369436B (zh) * 2009-02-05 2014-10-22 生物基因Idecma公司 用于检测jc多瘤病毒的方法
WO2010099205A1 (en) 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
EP2226392A1 (en) * 2009-03-03 2010-09-08 Assistance Publique - Hôpitaux de Paris Method for detecting JCV infection
WO2011124652A1 (en) * 2010-04-08 2011-10-13 Fondazione Centro San Raffaele Del Monte Tabor Immunodominant peptide of polyomavirus jc and uses thereof

Also Published As

Publication number Publication date
AU2012288955B2 (en) 2017-06-08
US9738690B2 (en) 2017-08-22
EP2734218A2 (en) 2014-05-28
KR20140062702A (ko) 2014-05-26
US20140356320A1 (en) 2014-12-04
WO2013014134A3 (en) 2013-05-02
NZ620196A (en) 2016-10-28
AU2012288955A1 (en) 2014-02-20
CN103826653A (zh) 2014-05-28
JP2014520877A (ja) 2014-08-25
WO2013014134A2 (en) 2013-01-31
HK1198517A1 (en) 2015-05-15
EA201490322A1 (ru) 2014-05-30
CA2842543A1 (en) 2013-01-31
EP2548567A1 (en) 2013-01-23
MX2014000776A (es) 2014-11-26

Similar Documents

Publication Publication Date Title
BR112014001516A2 (pt) peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
BR112019010972A2 (pt) receptores de células t e imunoterapia usando os mesmos
BR112014017111A2 (pt) métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
BR112012019881A2 (pt) proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BRPI0909123B8 (pt) anticorpos monoclonais, vetor de expressão, célula hospedeira, composição farmacêutica, uso do referido anticorpo, kit de diagnóstico e métodos de ensaio para detectar a presença de epítopos de vírus de influenza a
BR112012022688A2 (pt) proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão
BR112015023105A2 (pt) construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a?
BR112014017862A2 (pt) epitopos modificados para aumento de respostas de célula t cd4+
IN2014DN10288A (pt)
EA201000424A1 (ru) Антитела к il-23
Marfe et al. Effectiveness of COVID‑19 vaccines and their challenges
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
BR112013005427A2 (pt) composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica.
WO2017096327A3 (en) Compositions and methods for reducing immune responses against chimeric antigen receptors
BR112018000653A2 (pt) anticorpo anti-cd154 tendo características melhoradas de ligação, funcionais e de segurança e uso na imunoterapia humana
BR112016011930A2 (pt) combinações de peptídeos e seus usos em tratamento de alergia de ácaro de poeira
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
BR112018016912A2 (pt) novo antígeno para uso na vacina contra malária

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.